GSK (GLAXF) YoY EPS Growth: 11.81% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GLAXF GSK PLC GLAXF
69 GF Score
Price $25.31
GF Value $21.88
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GSK YoY EPS Growth?

GSK GLAXF 69 YoY EPS Growth is 11.81% as of Mar. 2026. GuruFocus rates GLAXF with a GF Score™ of 69/100 and a GF Value™ of $21.88 (Modestly Overvalued). The stock has 1 warning sign investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. GSK's YoY EPS Growth for the quarter that ended in Mar. 2026 was 11.81%.

GSK's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was $0.57.

GSK YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for GSK's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK YoY EPS Growth Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.93 209.94 -65.96 -48.22 136.39

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.28 31.13 3,594.74 65.87 11.81
GLAXF
69GF Score
GSK PLC GLAXF
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

GSK's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(1.858-0.786)/ | 0.786 |
=136.39 %

GSK's YoY EPS Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EPS Growth (Q: Mar. 2026 )
=(Earnings per Share (Diluted) (Q: Mar. 2026 )-Earnings per Share (Diluted) (Q: Mar. 2025 )) / | Earnings per Share (Diluted) (Q: Mar. 2025 )) |
=(0.568-0.508)/ | 0.508 |
=11.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 11.81% mean?
GSK (GLAXF) has a YoY EPS Growth of 11.81% as of Mar. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for GSK and its competitors.
Is GSK's YoY EPS Growth too high?
GSK's current YoY EPS Growth is 11.81%. Overall, GSK has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's YoY EPS Growth compare to LLY and JNJ?
GSK's YoY EPS Growth of 11.81% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Drug Manufacturers company?
A good YoY EPS Growth depends on the Drug Manufacturers industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for GSK and its competitors. GSK's current YoY EPS Growth is 11.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.88, compared to a current price of $25.31 — trading 15.7% above its estimated fair value. The current YoY EPS Growth is 11.81%. GSK's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For GSK (GLAXF), the current YoY EPS Growth is 11.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (GLAXF) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of $25.31 is trading 15.7% above its estimated GF Value™ of $21.88. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for GLAXF:

  • YoY EPS Growth: 11.81%
  • GF Value™: $21.88 vs. price of $25.31 (15.7% above fair value)
  • GF Score™: 69/100 with 1 warning sign

No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
69GF Score

Get the complete analysis for GLAXF

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.31
Price
$21.88
GF Value